Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

From the plant

CBDPCannabidiphorol

Heptyl (C7) homologue of CBD, present in trace amounts; negative allosteric modulator of CB1 in vitro.

Unscheduled
Level of detail

C₂₃H₃₄O₂

CAS 55824-13-0

Family
PhytocannabinoidMinor
Origin
Decarboxylation
Molar mass
342.52 g/mol

Updated on

In plain terms

Cannabidiphorol is a CBD whose side chain has seven carbons instead of five. Discovered in 2019 in a medicinal cannabis variety, it is present there only in very small amounts. In the laboratory, its receptor profile closely resembles that of CBD; no human study has been published.

Receptors and activity

Target network

CB1Negative allosteric modulatornegative allosteric modulator: rightward shift and reduced Emax of CP55940 (cAMP inhibition, CHO-K1-hCB1), two allosteric sites proposed (Pandey et al. 2026); weak antagonism, IC50 not reached up to about 12 µM (Haghdoost et al. 2024)
  • Activates
  • Blocks or inhibits

The lower the cited value, the closer the target sits to CBDP: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of CBDP.

Brain, side view
Body, front view
Blood

CB1CB1 found in 7 regions of the body

  1. Basal gangliadenseMost dense in basal ganglia outflow nuclei1
  2. CerebellumdenseVery dense in the cerebellum1
  3. HippocampusdenseVery high concentrations in the hippocampus2
  4. AmygdaladenseHigh concentrations in the amygdala2
  5. CortexpresentPresent throughout the neocortex2
  6. Adipose tissuepresentExpressed in adipose tissue3
  7. GutpresentColonic epithelium, smooth muscle and plexus4

Map sources

  1. Herkenham M et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A, 1990 (new tab)
  2. Glass M et al. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 1997 (new tab)
  3. Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
  4. Wright K et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005 (new tab)

Cited values

  1. CB1Negative allosteric modulatorno measured value cited

    negative allosteric modulator: rightward shift and reduced Emax of CP55940 (cAMP inhibition, CHO-K1-hCB1), two allosteric sites proposed (Pandey et al. 2026); weak antagonism, IC50 not reached up to about 12 µM (Haghdoost et al. 2024)

  2. CB2Antagonistno measured value cited

    weak antagonism, IC50 not reached up to about 12 µM, slightly weaker than that of CBD; about 50% displacement of [3H]CP55940 at 1 µM (Haghdoost et al. 2024)

  3. 5-HT1AAgonistno measured value cited

    very weak agonism: about 20% of the maximal serotonin response at 12 µM, EC50 above 12 µM (Haghdoost et al. 2024)

  4. MORPositive allosteric modulatorno measured value cited

    increase in mu-opioid receptor internalisation induced by met-enkephalin (1 µM) in the presence of 3 µM CBDP, a positive-modulator-type effect; only one concentration tested (Haghdoost et al. 2024)

Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Measured effects

Not characterised. No placebo-controlled human trial has measured the effects of CBDP, so no level is shown.

Levels computed from placebo-controlled human trials: difference from placebo on 100, at the dose and route stated. Read the method

Pharmacology

Cannabidiphorol (CBDP) is the heptyl-chain (C7) homologue of cannabidiol. Citti, Cannazza and colleagues isolated it in 2019 from the Italian medicinal cannabis variety FM2, together with Δ9-THCP, and identified it by comparison with the synthetic standard; its content there was about 243 µg/g, versus 56 mg/g for CBD. Its acid, CBDPA, was then quantified in 49 samples from four chemotypes (Linciano et al. 2021). Contrary to the idea that a longer chain makes the molecule more potent, one in vitro study found a profile very close to that of CBD: weak antagonism at CB1 and CB2, with no IC50 reached up to about 12 µM, very weak agonism at 5-HT1A and no agonism at the D2S receptor (Haghdoost et al. 2024). At human CB1, it behaved as a negative allosteric modulator, engaging two distinct sites according to mutagenesis and molecular dynamics (Pandey et al. 2026). No human data have been published, although Haghdoost et al. report it on sale in North America. Together with CBDH, its presence in a CBD sample is taken as a sign of natural origin (Brighenti et al. 2024).

Key sources.

History

Source
Cannabis sativa L.: a constituent present in trace amounts. Isolated in 2019 from the Italian medicinal variety FM2, where its content was estimated at about 243 µg/g (Citti et al. 2019); its acid, CBDPA, was quantified in 49 samples from four chemotypes (Linciano et al. 2021).

Biosynthetic pathway

CBDP is the neutral form produced by decarboxylation of its acid, CBDPA, which fresh inflorescence contains (Linciano et al. 2021). The enzyme or starter unit that supplies the heptyl chain has not been characterised in the plant.

Classification

Family, origin and source verification

Family

Phytocannabinoid › Minor

Presence in the plant

Neutral form: decarboxylation of a plant acid

Chemistry

Type CBD · C7 side chain · neutral form

Verification

Every fact on this entry was checked against its primary sources on 20 October 2026.

Wikipedia (English)

Cannabidiphorol (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

References

  1. Citti C. et al., isolation of Δ9-THCP and CBDP from the FM2 variety, Sci Rep 2019, 9:20335 (new tab)PMID 31889124
  2. Linciano P. et al., phorolic cannabinoid acid content (CBDPA, THCPA) in 49 Cannabis sativa L. samples, Talanta 2021, 235:122704 (new tab)PMID 34517579
  3. Haghdoost M. et al., CBD and CBDP: comparison of in vitro receptor activities, Int J Mol Sci 2024, 25:7724 (new tab)PMID 39062976
  4. Pandey P. et al., cannabidiphorol, a two-site negative allosteric modulator of the CB1 receptor, Commun Chem 2026, 9:186 (new tab)PMID 41904334
  5. Salbini M. et al., oxidative stress and organelle damage induced by CBDB and CBDP in breast cancer cells, Molecules 2021, 26:5576 (new tab)PMID 34577048
  6. Brighenti V. et al., impurity profile and distinction between natural and synthetic CBD, Anal Bioanal Chem 2024, 416:4555-4569 (new tab)PMID 38940871
  7. ANSM, consolidated list of substances classified as narcotics (26/06/2026) (new tab)
  8. PubChem CID 49873141: cannabidiphorol (CAS 55824-13-0 according to EPA DSSTox and ECHA) (new tab)

Identifiers

Names

Common name
Cannabidiphorol
IUPAC name
5-heptyl-2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]benzene-1,3-diol
Other names
CBDP · CBD-C7 · CBD heptylique

Identifiers

Formula
C₂₃H₃₄O₂
CAS
55824-13-0
PubChem CID
49873141(new tab)
InChIKey
GGHRHCGOMWNLCE-VQTJNVASSA-N
SMILES
CCCCCCCC1=CC(=C(C(=C1)O)[C@@H]2C=C(CC[C@H]2C(=C)C)C)O

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.